![](https://endpts.com/wp-content/uploads/2023/05/John-Butler-Akebia-tile.jpg)
John Butler, Akebia Therapeutics CEO
Updated: FDA approves Akebia's anemia drug after saying no in 2022
The FDA on Wednesday greenlit Akebia Therapeutics’ treatment for anemia due to chronic kidney disease, marking a turnaround for vadadustat, which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.